Afya Limited (NASDAQ:AFYA) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1 year consensus price objective of $30.73 for the company and are forecasting that the company will post $0.17 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Afya an industry rank of 110 out of 256 based on the ratings given to related companies.

A number of research firms recently commented on AFYA. Bank of America began coverage on Afya in a research report on Tuesday, August 13th. They set a “buy” rating and a $29.00 price objective for the company. Goldman Sachs Group began coverage on Afya in a research report on Tuesday, August 13th. They set a “neutral” rating and a $26.00 price objective for the company. JPMorgan Chase & Co. began coverage on Afya in a research report on Friday, August 9th. They set an “overweight” rating and a $34.00 price objective for the company. Finally, Morgan Stanley began coverage on Afya in a research report on Tuesday, August 13th. They set an “overweight” rating and a $29.20 price objective for the company.

Afya stock traded up $1.26 during midday trading on Tuesday, reaching $28.29. 337,344 shares of the company were exchanged, compared to its average volume of 354,307. Afya has a 1 year low of $22.00 and a 1 year high of $29.37.

Afya Company Profile

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company provides educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

Featured Story: What is Elliott Wave theory?

Get a free copy of the Zacks research report on Afya (AFYA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.